George Kemble is Director at Sagimet Biosciences Inc. (SGMT). They have made 1 open-market trade across 1 company since 2024, most recently 2026-08-14.
CIK 0001858176
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| SGMT | 62,161 | $499K |
Shares reported on the most recent Form 4, priced at the 2026-08-17 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SGMT | SELL · 10b5-1 | 2026-08-14 | 2026-08-17 | $10.23 | $3.6M | +0.7% | -2.1% | — |
| SGMT | SELL · 10b5-1 | 2026-08-11 | 2026-08-12 | $9.95 | $201K | +7.0% | +13.9% | — |
| SGMT | SELL · 10b5-1 | 2026-07-20 | 2026-07-22 | $7.46 | $141K | +1.9% | +45.8% | — |
| SGMT | SELL · 10b5-1 | 2025-11-20 | 2025-11-21 | $7.69 | $580K | -5.2% | -6.9% | -19.7% |
| SGMT | SELL · 10b5-1 | 2024-07-23 | 2024-07-25 | $3.17 | $150K | -18.4% | -10.4% | +62.8% |
| SGMT | SELL | 2024-07-19 | 2024-07-23 | $3.10 | $44K | -5.2% | -10.2% | +71.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.